EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer

Muhammad Ali, Kendrick Koo, David Chang, Phil Chan, Sheng F Oon, Daniel Moon, Declan G Murphy, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Arun A Azad, Sarat Chander und 3 weitere

Radiation Oncology · 2024

DOI: 10.1186/s13014-024-02413-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Oncology, 2024. Verfasst von Muhammad Ali und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. muhammad.ali@petermac.org. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical factors predictive of severe to end-stage chronic kidney disease (CKD) after SABR for RCC. Methods and materials This was a Single institutional retrospective analysis of patients with diagnosed primary RCC receiving SABR between 2012–2020. Adult patients with no metastatic disease, baseline estimated glomerular filtration rate (eGFR) of ≥ 30 ml/min/1.73 m 2 , and at least one post-SABR eGFR at six months or later were included in this analysis. Patients with upper tract urothelial carcinoma were excluded. Primary outcome was freedom from severe to end-stage CKD, determined using the Kaplan–Meier estimator. The impact of baseline CKD, age, hypertension, diabetes, tumor size and fractionation schedule were assessed by Cox proportional hazard models.

Results

Seventy-eight consecutive patients were included, with median age of 77.8 years (IQR 70–83), tumor size of 4.5 cm (IQR 3.9–5.8) and follow-up of 42.2 months (IQR 23–60). Baseline median eGFR was 58 mls/min; 55% (n = 43) of patients had baseline CKD stage 3 and the remainder stage 1–2. By last follow-up, 1/35 (2.8%) of baseline CKD 1–2, 7/27 (25.9%) CKD 3a and 11/16 (68.8%) CKD 3b had developed CKD stage 4–5. The estimated probability of freedom from CKD stage 4–5 at 1 and 5 years was 89.6% (CI 83.0–97.6) and 65% (CI 51.4–81.7) respectively. On univariable analysis, worse baseline CKD ( p < 0.0001) and multi-fraction SABR ( p = 0.005) were predictive for development of stage 4–5 CKD though only the former remained significant in multivariable model.

Conclusion

In this elderly cohort with pre-existing renal dysfunction, SABR achieved satisfactory nephron sparing with acceptable rates of severe to end-stage CKD. It can be an attractive option in patients who are medically inoperable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsCarcinoma, Transitional CellUrinary Bladder NeoplasmsRadiosurgeryKidney Failure, ChronicRenal Insufficiency, ChronicAdultHumansAgedAged, 80 and overRetrospective Studies

Stichwörter der Autor:innen

Chronic kidney diseaseEnd-stage renal diseaseRCCRenal cell carcinomaSABRStereotactic ablative radiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. muhammad.ali@petermac.org.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. muhammad.ali@petermac.org.
  • Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.

Zitieren

APA

Ali, M., Koo, K., Chang, D., Chan, P., Oon, S. F., Moon, D., Murphy, D. G., Eapen, R., Goad, J., Lawrentschuk, N., Azad, A. A., Chander, S., Shaw, M., Hardcastle, N., & Siva, S. (2024). Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer. Radiation Oncology. https://doi.org/10.1186/s13014-024-02413-w

Vancouver

Ali M, Koo K, Chang D, Chan P, Oon SF, Moon D, et al. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer. Radiation Oncology. 2024. doi:10.1186/s13014-024-02413-w

BibTeX
@article{Ali2024,
  author = {Ali, Muhammad and Koo, Kendrick and Chang, David and Chan, Phil and Oon, Sheng F and Moon, Daniel and Murphy, Declan G and Eapen, Renu and Goad, Jeremy and Lawrentschuk, Nathan and Azad, Arun A and Chander, Sarat and Shaw, Mark and Hardcastle, Nicholas and Siva, Shankar},
  title = {Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer},
  journal = {Radiation Oncology},
  year = {2024},
  doi = {10.1186/s13014-024-02413-w}
}
Kostenlos starten →